CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues:
Total revenues	$ 6,954	$ 6,599	$ 13,640	$ 12,951
Costs and expenses:
Cost of goods sold	1,544	1,442	3,096	2,843
Research and development expenses	1,351	1,407	2,871	2,854
Acquired in-process research and development expenses	38	236	4,169	717
In-process research and development impairment	0	0	2,430	0
Selling, general and administrative expenses	1,377	1,849	2,752	3,168
Total costs and expenses	4,309	4,934	15,317	9,581
Operating income (loss)	2,644	1,665	(1,678)	3,370
Interest expense	237	230	491	459
Other (income) expense, net	355	(152)	265	22
Income (loss) before income taxes	2,053	1,588	(2,433)	2,888
Income tax expense	438	549	123	865
Net income (loss)	1,614	1,039	(2,556)	2,024
Net loss attributable to noncontrolling interest	0	(6)	0	(32)
Net income (loss) attributable to Gilead	$ 1,614	$ 1,045	$ (2,556)	$ 2,055
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.29	$ 0.84	$ (2.05)	$ 1.65
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,247	1,249	1,247	1,249
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.29	$ 0.83	$ (2.05)	$ 1.63
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,251	1,258	1,247	1,260
Product sales
Revenues:
Total revenues	$ 6,912	$ 6,564	$ 13,559	$ 12,870
Royalty, contract and other revenues
Revenues:
Total revenues	$ 41	$ 35	$ 81	$ 81